Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression-Reference-Cited by-同舟云学术

Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression

Published:2023-02 Issue:4 Volume:19 Page:279-287
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Malik Aleena¹,Jairam Meghan P²,Chow Ronald¹³^ORCID,Mirshahvalad Seyed A¹,Veit-Haibach Patrick¹,Simone Charles B³^ORCID

Affiliation:

1. Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada

2. Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA

3. New York Proton Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Abstract

Aim: The aim of this meta-regression was to assess the impact of mean/median age, mean/median tumor size, percentage of males in total sample, and total sample size on the comparative effectiveness of radiofrequency ablation (RFA) and stereotactic body radiation therapy (SBRT). Methods: Ten studies reporting on the composite outcome of overall survival and local control were included. Results: A significant relationship was found between age and overall survival at 1 and 2 for both RFA and SBRT. A significant relationship was noted also between age and local control at 1 and 2 years for RFA. Conclusion: Patients treated with SBRT had a wider range of tumor sizes and larger tumor sizes; no relationship was observed between tumor size and overall survival or local control by SBRT.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2022-0893

Reference40 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. International trends in hepatocellular carcinoma incidence, 1978–2012

3. The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective

4. New advances in the diagnosis and management of hepatocellular carcinoma